Table 1.
Participant baseline characteristics by availability of blood culture specimens
| Without blood culture specimens, non-test-negative design sample (n=21 664) | With blood culture specimens, test-negative design sample (n=6218) | Total, randomised controlled trial per-protocol sample (n=27 882) | p value | ||
|---|---|---|---|---|---|
| Vaccine group | 0·64 | ||||
| MenA | 10 812 (49·9%) | 3125 (50·3%) | 13 937 (50·0%) | .. | |
| Vi-TT | 10 852 (50·1%) | 3093 (49·7%) | 13 945 (50·0%) | .. | |
| Sex | 0·95 | ||||
| Male | 10 635 (49·1%) | 3049 (49·0%) | 13 684 (49·1%) | .. | |
| Female | 11 029 (50·9%) | 3169 (51·0%) | 14 198 (50·9%) | .. | |
| Age, years | <0·0001 | ||||
| Mean (SD) | 6·5 (3·2) | 4·7 (3·1) | 6·1 (3·3) | .. | |
| Median (IQR) | 7 (4–9) | 4 (2–7) | 6 (3–9) | .. | |
| Range | 0·8–12·0 | 0·8–12·0 | 0·8–12·0 | .. | |
| Age categories, years | <0·0001 | ||||
| <5 | 6759 (31·2%) | 3443 (55·4%) | 10 202 (36·6%) | .. | |
| ≥5 | 14 905 (68·8%) | 2775 (44·6%) | 17 680 (63·4%) | .. | |
| Study site | <0·0001 | ||||
| Ndirande | 13 771 (63·6%) | 3739 (60·1%) | 17 510 (62·8%) | .. | |
| Zingwangwa | 7893 (36·4%) | 2479 (39·9%) | 10 372 (37·2%) | .. | |
Data are n (%), unless otherwise indicated. MenA=meningococcal capsular group A conjugate vaccine. Vi-TT=typhoid Vi polysaccharide-tetanus toxoid-conjugate vaccine.